Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease

Citation:

Sbarouni E, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. Eur.Heart J. [Internet]. 2000;21(12):975 - 980.

Abstract:

AIMS: To assess the effect of simvastatin, hormone replacement therapy and their combination on soluble cell adhesion molecules and plasma lipids, in hypercholesterolaemic post-menopausal women with coronary artery disease. METHODS: We studied 16 post-menopausal women with coronary artery disease and hypercholesterolaemia (total cholesterol >200mg x dl(-1) and LDL cholesterol >130 mg x dl(-1)). We compared simvastatin (20 mg daily) with hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily) and their combination, in a randomized, crossover, placebo controlled study. Each treatment period was 8 weeks long with a 4 week washout interval between treatments. Circulating cell adhesion molecules and plasma lipids were evaluated at the end of each treatment period. RESULTS: All three active treatments--simvastatin, hormone replacement therapy and the combination therapy--significantly reduced total and LDL cholesterol, compared to placebo (P<0.001). Only hormone replacement therapy, alone and in combination with simvastatin, significantly decreased lipoprotein(a) when compared to placebo (P<0.05), whereas simvastatin had no significant effect. Likewise, hormone replacement therapy and the combination therapy significantly reduced the intercellular adhesion molecule (ICAM-1) plasma levels (P=0.03 and P=0.02, respectively), while simvastatin, which was superior to hormone replacement therapy in lowering total and LDL cholesterol, did not modify ICAM-1 levels; the combination therapy was not more effective than hormone replacement therapy alone in ICAM-1 reduction. Neither the effect, on any treatment when compared to placebo, of VCAM-1 nor E-selectin levels differed significantly. CONCLUSIONS: Hormone replacement therapy may limit the inflammatory response to injury by modulating the expression of cell adhesion molecules from the endothelial cells, possibly in association with lipoprotein (a) reduction

Notes:

DA - 20001018 IS - 0195-668X (Print) IS - 0195-668X (Linking) LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial RN - 0 (Anticholesteremic Agents) RN - 0 (Cell Adhesion Molecules) RN - 0 (Cholesterol, LDL) RN - 0 (Estrogens, Conjugated (USP)) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - AGG2FN16EV (Simvastatin) RN - C2QI4IOI2G (Medroxyprogesterone Acetate) SB - IM

Website